+

WO1996040213A1 - Production et purification de peptides - Google Patents

Production et purification de peptides Download PDF

Info

Publication number
WO1996040213A1
WO1996040213A1 PCT/US1996/009579 US9609579W WO9640213A1 WO 1996040213 A1 WO1996040213 A1 WO 1996040213A1 US 9609579 W US9609579 W US 9609579W WO 9640213 A1 WO9640213 A1 WO 9640213A1
Authority
WO
WIPO (PCT)
Prior art keywords
ser
lipopeptide
phe
peptide
lys
Prior art date
Application number
PCT/US1996/009579
Other languages
English (en)
Inventor
Ralph T. Kubo
Thomas Arrhenius
Original Assignee
Cytel Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corporation filed Critical Cytel Corporation
Priority to AU61038/96A priority Critical patent/AU6103896A/en
Publication of WO1996040213A1 publication Critical patent/WO1996040213A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to improved methods for the manufacture and purification of peptides.
  • it relates to methods of purifying lipopeptides useful as peptide-based therapeutics.
  • Cytotoxic T lymphocytes are important in the elimination of unwanted cells such as viral infected or neoplastic cells. CTLs specifically recognize and kill cells which are infected by a virus or which express certain tumor related antigens.
  • the anti-viral or anti-tumor activity of CTL is the result of a series of complex molecular events. After cellular processing of proteins in the cytoplasm of the virally infected cells or tumor cells, small peptides are transported to the endoplasmic reticulum, where they bind to newly synthesized major histocompatibility gene complex (MHC) class I molecules. MHC/peptide complexes are then exported to the surface of the cell, where they are recognized by antigen-specific Class I-restricted CTL.
  • MHC major histocompatibility gene complex
  • Immunologists have long been interested in the induction of specific CTL responses for the treatment of disease. For instance, in vivo induction of anti-viral CTL may be achieved by injection of live viruses. This procedure, however, bears two major disadvantages: 1) risk of induction of some form of the disease, and 2) lack of direct control over CTL epitope specificity.
  • the present invention provides methods for preparing purified synthetic lipopeptides.
  • the methods comprise contacting a composition comprising the synthetic lipopeptide with an aqueous solution, such that impurities are selectively dissolved.
  • the lipopeptide is then separated, typically by centrifugation, from the aqueous solution to obtain a purified lipopeptide.
  • the aqueous solution typically comprises an organic acid, such as acetic acid.
  • a preferred aqueous solution is 50% acetic acid/50% water.
  • the steps of contacting the lipopeptide with the aqueous solution may be repeated, typically about 5 times.
  • the lipopeptide comprises two lipid residues.
  • the lipid residue may be any lipid moiety, a exemplary lipid is a palmitoyl residue.
  • the lipopeptide may be of any length, but typically comprises between about 10 and about 35 amino acid residues.
  • the lipopeptide is typically an immunogenic peptide and thus comprises a CTL epitope, such as one from the hepatitis B virus core antigen.
  • a CTL eptitope is Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val.
  • the lipopeptide may also comprise a T helper eptitope.
  • An exemplary T helper epitope is Gln-Tyr-Ile-Lys-Ala-Asn- Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu.
  • a preferred lipopeptide is (PAM) Lys-Ser-Ser-Gln-Tyr- ⁇ e-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly- ⁇ e-Thr-Glu-Ala-Ala-AJa-Phe-I_eu-Pro-Ser--Asp-Phe- Phe-Pro-Ser-Val.
  • compositions comprising the purified lipopeptides of the invention.
  • the compositions consist essentially of DMSO, TFA and a lipopeptide having the formula: (PAM) 2 -Lys-Ser-Ser-Gln-Tyr-ne-Lys-Ala-Asn-Ser-Lys-Phe-ne-Gly-Ile-Thr-Glu-Ala-Ala- Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val.
  • PAM lipopeptide having the formula: (PAM) 2 -Lys-Ser-Ser-Gln-Tyr-ne-Lys-Ala-Asn-Ser-Lys-Phe-ne-Gly-Ile-Thr-Glu-Ala-Ala- Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val.
  • peptide is used interchangeably with “oligopeptide” in the present specification to designate a series of residues, typically L-amino acids, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of adjacent amino acids.
  • immunogenic peptide is a peptide that will bind an MHC molecule and induce a CTL response.
  • the immunogenic peptides of the invention are less than about 50 residues in length and usually consist of between about 10 and about 45 residues, preferably between about 20 and about 35 residues.
  • the immunogenic peptides comprise a peptide comprising a CTL eptitope covalently linked to a T helper peptides.
  • Particularly preferred CTL inducing peptides/T helper conjugates are linked by a spacer molecule.
  • a “lipopeptide” as used herein refers to a peptide, preferably an immunogenic peptide, covalently linked to a lipid residue.
  • a lipid residue is any residue derived from an organic molecule, including, fats, oils, waxes, and the like, which is relatively insoluble in water but soluble in common organic nonpolar solvents.
  • An impurity or contaminant is "selectively dissolved" in an aqueous solution as compared to the lipopeptides of the invention if the impurity is essentially completely in solution, such that after separation of the lipopeptide from the solution, the ⁇ ntaminant is not detectable in the lipopeptide composition by standard techniques such as HPLC.
  • a chromatogram as shown in Figure 3 shows the degree of purity of the final lipopeptide product.
  • the contaminants will be byproducts of peptide synthesis, such as uncompleted peptide chains.
  • the differential solubility of the uncompleted chains is enhanced by the capping procedure used during peptide synthesis.
  • purified peptide or “purified lipopeptide” refers to material which is free from contaminants such as uncompleted peptide chains as ascertained by standard techniques such as HPLC described above.
  • the purified peptides or lipopeptides of the invention are sufficiently free of contaminating material to suitable for administration to humans.
  • Figure 1 is a flow chart showing the process steps in the purification of a lipopeptide of the invention, CY-1899.
  • Figure 2 shows a typical HPLC profile of CY-1899 Palmitoylated Peptide Powder (unpurified). The major peak (approximately 31 minutes) corresponds to CY- 1899. Several impurities can also be observed in the chromatogram.
  • the cnromatographic conditions are as follows: Sample concentration - 10 mg/mL in DMSO + 0.1% TFA. Injection volume - 5 ⁇ L column - Zorbax 300SB-CN, 5 /.M, 30 nm pore, 150 mm 4.6mm. Mobile Phase - A: 20% Acetonitrile, 79.9% water, 0.1% Trifluoroacetic acid, B: 99.9% Acetonitrile, 0.1% trifluoroacetic acid. Column temperature 60°C. Gradient - 5% to 100% B in 45 minutes. How rate - 1 mL min. Detection - TJV at 214 nm.
  • Figure 3 shows the results of HPLC chromatography of CY-1899 Bulk Drug Substance after purification.
  • CY-1899 Bulk Drug Substance was dissolved in DMSO/0.1% TFA at 5mg/mL.
  • the sample (l l) was applied to a Zorbax 300SB-CN HPLC column (50 mm X 4.6mm).
  • the column temperature was 60°C
  • the flow-rate was 1.0 rr___ rnin
  • the eluate was monitored at 214 nm.
  • Buffer A was 20% acetonitrile, 80% water and 0.1% trifluoroacetic acid.
  • Buffer B was 100% acetonitrile containing 0.095% trifluoracetic acid.
  • the initial conditions were 95% buffer A and 5% buffer B.
  • the gradient was 5% buffer B isocratic for 10 minutes, from 5% B to 100% B over 45 minutes followed by isocratic 100% B for 10 minutes.
  • FIG. 4 shows the results of Mass Spectral Analysis of CY-1899 Contaminants.
  • a mixture of several impurities was obtained by fractionation by semi- preparative HPLC chromatography of Palmitoylated Peptide Powder before purification of CY-1899.
  • High resolution ion spray mass spectrometric analysis of this sample indicated the presence of at least 3 compounds.
  • the structures have not yet been elucidated.
  • the sodium adducts of the molecular ions M, Ml and M2 are designated as M-Na, M*-Na, and M 2 -Na.
  • Figure 5 shows mass spectrometric analysis of CY-1899.
  • High resolution FAB+ mass spectrometric analysis prior to purification of CY-1899 indicates the presence of a number of impurities, several of which can be identified as non-palmitoylated, acetylated peptides, which arise as a result of the capping procedure used during the synthesis.
  • the present invention provides improved methods for the production of peptide-based vaccines and therapeutic agents.
  • the peptides of the invention comprise T cell epitopes from any desired antigen, for which the amino acid sequence of the antigen is known.
  • Epitopes derived from a number of potential target proteins can be used.
  • suitable antigens include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens and human papilloma virus (HPV) antigens.
  • PSA prostate specific antigen
  • HBVc hepatitis B core and surface antigens
  • HBVs hepatitis C antigens
  • Epstein-Barr virus antigens Epstein-Barr virus antigens
  • melanoma antigens e.g., MAGE-1
  • human immunodeficiency virus (HIV) antigens e.g., HBV antigens
  • HPV human papilloma virus
  • each residue is generally represented by standard three letter or single letter designations.
  • the L-form of an amino acid residue is represented by a capital single letter or a capital first letter of a three-letter symbol, and the D-form for those amino acids is represented by a lower case single letter or a lower case three letter symbol.
  • Glycine has no asymmetric carbon atom and is simply referred to as "Gly" or G.
  • the immunogenic peptides can be prepared synthetically, or by recombinant DNA technology. As described in detail below, the peptides are preferably prepared using synthetic methods. Although the peptide will preferably be free of other naturally occurring host cell proteins and fragments thereof, the peptides are synthetically conjugated to lipid residues as described below.
  • the polypeptides or peptides can be a variety of lengths, either in their neutral (uncharged) forms or in forms which are salts, and either free of modifications such as glycosylation, side chain oxidation, or phosphorylation or containing these modifications, subject to the condition that the modification not destroy the biological activity of the polypeptides as herein described.
  • Peptides having the desired activity may be modified as necessary to provide certain desired attributes, e.g., improved pharmacological characteristics, while increasing or at least retaining substantially all of the biological activity of the unmodified peptide to bind the desired MHC molecule and activate the appropriate T cell.
  • the peptides may be subject to various changes, such as substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use, such as improved MHC binding.
  • the peptides can also be modified by extending or decreasing the compound's amino acid sequence, e.g., by the addition or deletion of amino acids.
  • the peptides or analogs of the invention can also be modified by altering the order or composition of certain residues, it being readily appreciated that certain amino acid residues essential for biological activity, e.g., those at critical contact sites or conserved residues, may generally not be altered without an adverse effect on biological activity.
  • the non-critical amino acids need not be limited to those naturally occurring in proteins, such as L- ⁇ -amino acids, or their D-isomers, but may include non-natural amino acids as well, such as B-7- ⁇ -amino acids, as well as many derivatives of L- ⁇ -amino acids.
  • Amino acid substitutions are typically of single residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final peptide. Substitutional variants are those in which at least one residue of a peptide has been removed and a different residue inserted in its place.
  • Substantial changes in function are made by selecting substitutions that are less conservative, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain.
  • substitutions which in general are expected to produce the greatest changes in peptide properties will be those in which (a) hydrophilic residue, e.g. seryl, is substituted for (or by) a hydrophobic residue, e.g.
  • leucyl isoleucyl, phenylalanyl, valyl or alanyl
  • a residue having an electropositive side chain e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl
  • a residue having a bulky side chain e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine.
  • the peptides of the invention can be combined via linkage to form polymers (multimers), or can be formulated in a composition without linkage, as an admixture. Where the same peptide is linked to itself, thereby forming a homopolymer, a plurality of repeating epitopic units are presented.
  • noncovalent linkages capable of forming intermolecular and intrastructural bonds are also contemplated.
  • Linkages for homo- or hetero-polymers or for coupling to carriers can be provided in a variety of ways well known to those of skill in the art.
  • the immunogenic peptides of the invention are combined or coupled with other peptides which present T-helper cell epitopes, i.e., T helper peptides comprising six to thirty amino acids containing a T helper epitope which from the envelope, core or other immunogenic protein or derivative thereof, stimulate T cells that cooperate in the induction of cytotoxic T cells to the target antigen.
  • T helper peptides comprising six to thirty amino acids containing a T helper epitope which from the envelope, core or other immunogenic protein or derivative thereof, stimulate T cells that cooperate in the induction of cytotoxic T cells to the target antigen.
  • Compositions of T- helper peptides and CTL peptides thereby enhance an individual's immunity by providing cell-mediated immunity and protective antibodies.
  • T helper epitopes are provided by peptides from, for example, tetanus toxoid 830-843, malaria circumsporozoite 382-398, malaria circumsporozoite 378-398, ovalbumin 323-336, and the influenza epitope 307-319 (see, WO 95/01000, WO 94/02353 and WO 92/07218, supra).
  • pan DR helper peptides can be used as the helper peptides.
  • Pan DR peptides are those recognized by a broad pattern of DR alleles.
  • the CTL inducing peptides of the invention are covalently linked to the T helper peptides.
  • Particularly preferred CTL inducing peptides/T helper conjugates are linked by a spacer molecule.
  • the CTL peptide may be linked to the T helper peptide without a spacer.
  • the spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions and may have linear or branched side chains.
  • the spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids.
  • the neutral spacer is Ala.
  • the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer.
  • Preferred exemplary spacers are homo-oligomers of Ala. When present, the spacer will usually be at least one or two residues, more usually three to six residues.
  • the peptides of the invention comprise at least one lipid residue which assists in priming CTL.
  • Lipids have been identified as agents capable of assisting the priming CTL in vivo against viral antigens.
  • various alkanoyl ( -C-o) lipids can be linked to the peptides via one or more linking residues.
  • palmitic acid residues can be attached to the alpha and epsilon amino groups of a Lys residue and then linked, e.g., via one or more linking residues such as Gly, Gly-Gly-, Ser, Ser-Ser, or the like, to an immunogenic peptide.
  • lipidated peptide can then be injected directly in a micellar form, incorporated into a liposome or emulsified in an adjuvant, e.g., incomplete Freund's adjuvant.
  • a particularly effective immunogen comprises palmitic acid (referred to as PAM) attached to alpha and epsilon amino groups of Lys, which is attached via linkage, e.g., Ser-Ser, to the amino terminus of the immunogenic peptide.
  • E. coli lipoproteins such as tripalrnitoyl-S-glycerylcysteinlyseryl-serine (P 3 CSS) can be used to prime virus specific CTL when covalently attached to an appropriate peptide.
  • P 3 CSS tripalrnitoyl-S-glycerylcysteinlyseryl-serine
  • P 3 CSS tripalrnitoyl-S-glycerylcysteinlyseryl-serine
  • the lipopeptides of the invention can be prepared in a wide variety of ways. Because of their relatively short size, the peptides can be synthesized in solution or on a solid support in accordance with conventional techniques. Alternatively, recombinant DNA technology may be employed wherein a nucleotide sequence which encodes an immunogenic peptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression. These procedures are generally known in the art, as described generally in Sambrook et al. , Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, New York (1982). As noted above, the preferred method of making the peptides of the invention is through synthetic means.
  • Solid phase peptide synthesis in which the C- terminal amino acid of the sequence is attached to an insoluble support followed by sequential addition of the remaining amino acids in the sequence is the preferred method for preparing the peptides of the present invention.
  • Techniques for solid phase synthesis are described by Barany and Merrifield, Solid-Phase Peptide Synthesis; pp. 3-284 in The Peptides: Analysis, Synthesis, Biology. Vol. 2: Special Methods in Peptide Synthesis, Part A., Merrifield, et al. J. Am. Chem. Soc. 85, 2149-2156 (1963), and Gross and Meienhofer, eds. Academic press, N.Y., 1980 and Stewart et al, Solid Phase Peptide Synthesis, 2nd ed. Pierce Chem. Co., Rockford, HI. (1984). Solid phase synthesis is most easily accomplished with commercially available peptide synthesizers utilizing, for example, Fmoc or Tboc chemistry.
  • the lipopeptides of the invention are produced by assembly of the lipopeptide from C-terminus to N-terminus on standard supports, Fmoc chemistry. After each residue is added to the growing oligopeptide chain, the chain is capped, according to standard procedures, e.g. , by reaction with acetic anhydride. This will ensure that any resin bound peptide chain that was not coupled with the last amino acid will be terminated. These terminated chains will then be removed at the final purification step of the lipopeptide due to their different physical properties from the lipopeptide in aqueous solutions.
  • CY1899 a preferred embodiment, referred to here as CY1899
  • lipopeptides can be prepared in essentially the same manner. For instance, the methods have also been shown to be effective for other lipopeptides such as (PAM) 2 _KSSA___XVAAWTLKAAAAAGIGILTV, where X is L-cyclohexylalanine. N-terminal lipidation is also carried out on the resin. Following assembly of the fully protected peptide, the desired product is cleaved from the resin with concomitant deprotection of the side chain protecting groups. Upon completion of the coupling cycles and cleavage from the solid support with trifluoroacetic acid (TFA), the lipopeptide is precipitated with diethyl ether.
  • TFA trifluoroacetic acid
  • lipopeptides of the invention is accomplished by suspending the lipopeptide in a polar solvent, typically aqueous solutions, such as water, aqueous solutions of weak organic acids, phosphate buffered saline (PBS), and normal saline (0.9% sodium chloride).
  • a polar solvent typically aqueous solutions, such as water, aqueous solutions of weak organic acids, phosphate buffered saline (PBS), and normal saline (0.9% sodium chloride).
  • PBS phosphate buffered saline
  • TFA trifluoroacetic acid
  • the relative insolubility of the lipopeptides in polar aqueous solutions provides a particularly convenient method for preparing purified lipopeptides.
  • any number of polar solvents can be used for this purpose, and the particular solvent is not critical, so long as the ⁇ ntarninants are much more soluble in the solution than the lipopeptides.
  • an aqueous solution comprising a weak organic acid, such as acetic acid is typically used.
  • a preferred solute is 50% acetic acid/water.
  • the lipopeptide unlike other reaction byproducts such as incomplete oligopeptide chains, is not soluble in the aqueous solution and is therefore recovered in purified form by separating it from the solution.
  • the lipopeptide can be recovered according to any method commonly used to recover insoluble material from a solution, typically by centrifugation.
  • the process may be repeated until the desired purity is obtained. In a typical embodiment, this will be include between about 2 washings and about 10 washings. Washing a total of about 5 times is usually sufficient to prepare lipopeptides of suitable purity. After repeated washing the lipopeptide is washed twice with water and the final pellet is resuspended in water and lyophilized. The lipopeptide is then dissolved in an appropriate solvent, such as DMSO.
  • an appropriate solvent such as DMSO.
  • the peptides of the present invention and pharmaceutical and vaccine compositions thereof are useful for administration to mammals, particularly humans, to treat and/or prevent viral infection and cancer.
  • diseases which can be treated using the immunogenic peptides of the invention include prostate cancer, hepatitis B, hepatitis C, AIDS, renal carcinoma, cervical carcinoma, lymphoma, CMV and condlyloma acuminatum.
  • the immunogenic peptides of the invention are administered to an individual already suffering from cancer or infected with the virus of interest. Those in the incubation phase or the acute phase of infection can be treated with the immunogenic peptides separately or in conjunction with other treatments, as appropriate.
  • compositions are administered to a patient in an amount sufficient to elicit an effective CTL response to the virus or tumor antigen and to cure or at least partially arrest symptoms and/or complications. An amount adequate to accomplish this is defined as "therapeutically effective dose.
  • Amounts effective for this use will depend on, e.g., the peptide composition, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician, but generally range for the initial immunization (that is for therapeutic or prophylactic administration) from about 1.0 ⁇ g to about 5000 ⁇ g of peptide for a 70 kg patient, followed by boosting dosages of from about 1.0 ⁇ g to about 1000 ⁇ g of peptide pursuant to a boosting regimen over weeks to months depending upon the patient's response and condition by measuring specific CTL activity in the patient's blood.
  • peptides and compositions of the present invention may generally be employed in serious disease states, that is, life- threatening or potentially life threatening situations. In such cases, in view of the minimization of extraneous substances and the relative nontoxic nature of the peptides, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions.
  • administration should begin at the first sign of viral infection or the detection or surgical removal of tumors or shortly after diagnosis in the case of acute infection. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. In chronic infection, loading doses followed by boosting doses may be required.
  • Treatment of an infected individual with the compositions of the invention may hasten resolution of the infection in acutely infected individuals.
  • the compositions are particularly useful in methods for preventing the evolution from acute to chronic infection.
  • the susceptible individuals are identified prior to or during infection, for instance, as described herein, the composition can be targeted to them, minimizing need for administration to a larger population.
  • the peptide compositions can also be used for the treatment of chronic infection and to stimulate the immune system to eUminate virus-infected cells in carriers. It is important to provide an amount of immuno-potentiating peptide in a formulation and mode of administration sufficient to effectively stimulate a cytotoxic T cell response.
  • a representative dose is in the range of about 1.0 ⁇ g to about 5000 ⁇ g, preferably about 5 ⁇ g to 1000 ⁇ g for a 70 kg patient per dose. Immunizing doses followed by boosting doses at established intervals, e.g., from one to four weeks, may be required, possibly for a prolonged period of time to effectively immunize an individual.
  • administration should continue until at least clinical symptoms or laboratory tests indicate that the viral infection has been eliminated or substantially abated and for a period thereafter.
  • compositions for therapeutic treatment are intended for parenteral, topical, oral or local administration.
  • the pharmaceutical compositions are administered parenterally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly.
  • the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier with an appropriate solvent such as DMSO/TFA.
  • an acceptable carrier preferably an aqueous carrier with an appropriate solvent such as DMSO/TFA.
  • aqueous carriers may be used, e.g., water, buffered water, PBS, 0.3% glycine, hyaluronic acid and the like.
  • compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
  • auxiliary substances such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
  • concentration of CTL stimulatory peptides of the invention in the final pharmaceutical formulations can vary widely, i.e., from less than about 0.1%, usually at or at least about 0.1 % to 0.5%, to as much as 10% to 15% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
  • the lipopeptide CY-1899 is a construct consisting of thirty L-amino acid residues and two palmitic acid residues.
  • the amino acids are covalently linked in a linear fashion through amide bonds.
  • the two palmitoyl (PAM) residues are linked to the N- terminus amino acid through amide bonds to the ⁇ and e amino groups of lysine.
  • composition of CY-1899 is as follows:
  • the ten amino acid sequence from the phenylalanine at residue 21 through the C-terminus valine forms the CTL epitope from hepatitis B virus core antigen.
  • a three amino acid linker consisting of alanines is used to connect the CTL epitope to the next sequence which is a fourteen amino acid sequence of tetanus toxoid that serves as a T cell helper epitope. This is followed by a three amino acid linker terminating in lysine.
  • the N- terminus lysine provides two amino groups to which palmitic acid is attached. In this way the construct contains three moieties: CTL epitope, T-helper epitope, and lipid group, covalently coupled together to give active CY-1899.
  • the lipid groups provide for particular physical properties of CY-1899. It is insoluble in water and soluble in methanol. This property allows for purification of CY- 1899 from water soluble impurities by the addition of water. CY-1899 is also insoluble in 50% acetic acid/water. The preferred purification scheme employs multiple washings in 50% acetic acid/water to remove soluble peptide and non-peptide contaminants from the crude peptide intermediate. CY-1899 is practically insoluble in water, phosphate buffered saline (PBS), and normal saline (0.9% sodium chloride).
  • PBS phosphate buffered saline
  • normal saline (0.9% sodium chloride
  • NMP N-methylpyrrolidone
  • the next Fmoc-amino acid required in the synthesis is converted into the activated 1-hydroxybenzotriazolyl ester (Fmoc-AA-OBt) form, in a separate vessel, by reaction with 1 -hydroxy benzotriazole (HOBt) and diisopropylcarbodiimide (DIC) in dimethyl acetamide (DMA) or NMP.
  • HOBt 1 -hydroxy benzotriazole
  • DIC diisopropylcarbodiimide
  • DMA dimethyl acetamide
  • NMP dimethyl acetamide
  • NMP or DMA as solvent is founded on the basis of its ability to solubilize all of the Fmoc-amino acids and activated esters used in this synthesis, as well as its propensity to break up secondary structure in the elongating peptide chain. The latter characteristic is helpful for the successful assembly of a peptide of the length of CY-1899.
  • the resin is sampled and tested with ninhydrin or tetrachloro-/7-benzoquinone reagent to assay for completion. This assay is capable of detecting 0.2% of unreacted amino group. If the coupling reaction is incomplete (less then 99.5%), a second coupling reaction is performed. If coupling is satisfactory then the peptide chain is capped by reaction with acetic anhydride. This will ensure that any resin bound peptide chain that was not coupled with the last amino acid will be terminated. These terminated chains will then be removed at the final purification step of the bulk drug substance due to their different physical properties from CY-1899. This ensures a high degree of sequence fidelity of CY-1899. Upon completion, the cycle is repeated until all of the amino acid constituents of CY-1899 are introduced. The palmitoyl groups are then introduced in a similar fashion.
  • the peptide is cleaved from the solid support, and all side chain protecting groups are removed by reacting a dried resin with TFA-water.
  • the ACT 200 Peptide Synthesizer is loaded with methylene chloride
  • the substitution level is determined by first removing the Fmoc group; then the amino acid substitution level of the resin is assayed by the ninhydrin method. This is lot specific.
  • the weighed resin is placed in a 500 mL reaction vessel which has been pre-silanized according to standard written procedures. Delivery and removal of reagents are made through the top and bottom delivery lines.
  • Preconditioning the Resin The manual mode is selected from the main menu and the wash selection is instructed to fill the reaction vessel with approximately 150 mL of N-methylpyrrolidone (NMP) and the filled vessel is sparged with nitrogen for 2-3 minutes. The vessel is emptied at that time and the wash step repeated twice more. This is done to precondition the resin to the solvent.
  • NMP N-methylpyrrolidone
  • Deprotection The delivery line is washed with 50 mL of NMP and then 110 mL of 25% piperidine in NMP is added to the reaction vessel and mixed with the resin for 5 minutes by sparging nitrogen through the solution. At that time the reaction vessel is emptied. Then 110 mL of 25% piperidine in NMP is added and mixed with the resin for 25 minutes with nitrogen sparging.
  • the resin in the reaction vessel is then washed twice consecutively with 150 mL of NMP for 2 minutes and 150 mL of isopropanol (IPA) for 2 minutes. A final 3 washes with 150 mL of NMP for 2 minutes ensures removal of piperidine. Finally the delivery line to the reaction vessel is washed with 50 mL of NMP. The efficiency of the Fmoc deprotection of the resin is then determined for all terminal amino acids, except proline, by a qualitative ninhydrin assay. When the terminal amino acid is proline, a qualitative assay with tetracrdoro-p-benzoquinone is conducted.
  • the Fmoc-amino acid to be coupled to the immobilized acceptor is converted to an active ester.
  • the active ester used in the synthesis of CY-1899 is the hydroxybenzotriazole ester.
  • 6-20 mmol of Fmoc-serine(tBu)-OH is mixed in a second glass reaction vessel with a 6-20 mmol of N- hydroxybenzotriazole and 30-40 mL of dimethylacetamide (DMA) or NMP (depending upon the amino acid) by vortexing until a complete solution is obtained.
  • DMA dimethylacetamide
  • NMP depending upon the amino acid
  • Spectroscopic analysis of the supernatant allows for quantitative determination of amines present. If the coupling efficiency is determined to be less than 99.5% then coupling of that residue is repeated. If coupling is found to be greater than or equal to 99.5%, the next step is conducted to effect capping of any residual free amine groups present. 6) Capping: The next step in the synthesis is conducted to react trace amounts ( ⁇ 1 %) of free amino groups that may be present. This will ensure that any resin bound peptide chain that was not coupled with the last amino acid will be terminated. These terminated chains will then be removed at the final purification step of the Bulk Drug Substance due to their different physical properties from CY-1899.
  • a fresh solution of 10% acetic anhydride in DMA is prepared and approximately 50-100 mL is added to the washed resin in the reaction vessel. This mixture is agitated for 35 minutes with nitrogen sparging. After agitation the reaction vessel is emptied and the resin is washed two times each with 150 mL of IPA, DCM, and NMP consecutively. This step completes one cycle of coupling. The first coupling step gives Fmoc-Ser(tBu)-Val-resin. This procedure is then repeated for the addition of the next amino acid residue in the sequence. This is continued until the final amino acid is added.
  • Palmitoylation The last coupling is the addition of two palmitic acid groups to the terminal lysine. Before adding the palmitic acid groups to the tridecapeptide, 100 to 300 mg of the peptide bearing resin is retained for cleavage to give a sample for amino acid sequencing. In a separate reaction vessel, a 4-fold excess of palmitic acid is reacted with a 2-fold excess diisopropylcarbodiimide in 70 mL of DCM and 15 mL of NMP to give the anhydride. This mixture is vortexed for 2 minutes and then left for 18-23 minutes. At that time the solution of palmitic anhydride is added to the resin and coupling carried out as described above.
  • the IPA and DCM washing steps are carried out as described above.
  • the efficiency of coupling of palmitic acid is determined as described above. If the degree of coupling is determined to be less then 99.5%, recoupling is carried out. This completes the chemical assembly of the peptide on the resin.
  • the next step is cleavage of the peptide from the resin and deprotection of the side chain residues of the peptide.
  • a 50 mL polypropylene centrifuge tube holding the Palmitovlated Peptide Powder Intermediate (unpurified) is labeled and stored at -70 * C in a secured area until use.
  • CY-1899 Palmitovlated Peptide Intermediate which is an unpurified drug substance, is purified by taking advantage of the differential solubility of CY-1899 and its related impurities in 50% acetic acid/water.
  • CY-1899 Palmitovlated Peptide Intermediate is insoluble in 50% acetic acid/ water while many of the impurities in CY-1899
  • Palmitovlated Peptide Intermediate are readily soluble and can be removed by washing with 50% acetic acid/ water.
  • Figure 1 outlines the process steps in the purification of CY-1899 drug substance.
  • CY-1899 Bulk Drug Substance The material described above is suspended at 10 ⁇ 5 mg/mL in 2-8 * C 50% acetic acid/water. The suspension is homogenized with a Brinkman Polytron unit for a total of 16 ⁇ 5 minutes at 25,000 RPM. The insoluble CY-1899 peptide is recovered by centrifugation at 10,000 X g for 30 ⁇ 15 minutes. This procedure is repeated an additional 4 times for a total of five 50% acetic acid/ water washes of the CY-1899 Palmitoylated Peptide Intermediate.
  • the CY-1899 Palmitoylated Peptide Intermediate is washed twice with water for irrigation to reduce the amount of residual acetic acid and allow efficient lyophilization.
  • the pellet from the 50% acetic acid/water wash is resuspended in an equal volume of water for irrigation and homogenized for 2-4 minutes to thoroughly resuspend the pellet.
  • the insoluble CY-1899 Palmitoylated Peptide is recovered by centrifugation for 60 ⁇ 30 minutes at 10,000 X g. This water wash is repeated for a total of two washes with water for irrigation.
  • the final pellet containing CY-1899 Palmitoylated Peptide is resuspended in an appropriate volume of water for irrigation and lyophilized. This lyophilized powder is CY-1899 Bulk Drug Substance.
  • This CY-1899 Bulk Drug Substance may be formulated immediately following appropriate in-process tests or stored at -70 * C.
  • the Bulk Drug Substance is stored in a glass or polypropylene container. The container is sealed in a mylar pouch containing a drying agent and stored at -70 "C.
  • the purity of CY-1899 is determined by high performance liquid chromatography (HPLC).
  • HPLC high performance liquid chromatography
  • the purity of the CY1899 bulk drug substance as compared to the unpurified palmitoylate peptide powder is shown in Figures 2 (unpurified) and 3 (purified).
  • Ion spray high resolution mass spectrometry of CY-1899 Bulk Drug Substance indicates the presence of numerous N-acetylated, truncated derivatives of the tridecapeptide ( Figure 4). These peptides are formed as a result of the capping procedure used during peptide synthesis.
  • Dosage Forms CY-1899 is provided in vials as a sterile, concentrated solution of CY-1899 in 99.9% DMSO/0.1 % TFA. Two concentrations are available: 10 mg/mL and 20 mg/mL.
  • a reconstitution diluent PBS [phosphate buffered saline], 2.5 mL/vial) and a dilution diluent (10% DMSO/0.01% TFA in PBS, 1.8 mL/vial) are provided for use in preparation of the final dosage form.
  • the final dosage form is prepared immediately prior to administration by mixing the sterile CY-1899 solution with the reconstitution diluent to yield a sterile suspension for injection.
  • the two dosage forms are described below. If necessary, the final dosage form suspension may be further diluted (with the dilution diluent) to obtain the desired dose.
  • Dosage Form A CY-1899 Suspension for Injection. 1 mg/mL CY-1899 concentrated solution: CY-1899 2 mg/0.2 mL vial (10 mg/mL)
  • the final dosage form suspension When reconstituted with 1.8 mL of PBS, the final dosage form suspension contains: CY-1899 1 mg/mL in 10% DMSO/0.01% TFA
  • Dosage Form B CY-1899 Suspension for Injection. 5 mg/mL
  • CY-1899 concentrated solution CY-1899 8 mg/0.4 mL vial (20 mg/mL)
  • the final dosage form suspension When reconstituted with 1.2 mL of PBS, the final dosage form suspension contains: CY-1899 5 mg/mL in 25% DMSO/0.025% TFA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des procédés de préparation de lipopeptides synthétiques purifiés. Ces procédés consistent à mettre une composition contenant le lipopeptide synthétique et divers agents de contamination en contact avec une solution aqueuse, de sorte que les impuretés soient dissoutes de manière sélective.
PCT/US1996/009579 1995-06-07 1996-06-05 Production et purification de peptides WO1996040213A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU61038/96A AU6103896A (en) 1995-06-07 1996-06-05 Manufacture and purification of peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48319695A 1995-06-07 1995-06-07
US08/483,196 1995-06-07

Publications (1)

Publication Number Publication Date
WO1996040213A1 true WO1996040213A1 (fr) 1996-12-19

Family

ID=23919073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/009579 WO1996040213A1 (fr) 1995-06-07 1996-06-05 Production et purification de peptides

Country Status (2)

Country Link
AU (1) AU6103896A (fr)
WO (1) WO1996040213A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2771640A1 (fr) * 1997-12-03 1999-06-04 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
WO2010086294A2 (fr) 2009-01-28 2010-08-05 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665053A (en) * 1983-05-16 1987-05-12 Centre National De La Recherche Scientifique Peptide derivatives, the preparation and their use as elastase inhibitors
US4666886A (en) * 1983-01-25 1987-05-19 Ciba-Geigy Corporation Novel peptide derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666886A (en) * 1983-01-25 1987-05-19 Ciba-Geigy Corporation Novel peptide derivatives
US4665053A (en) * 1983-05-16 1987-05-12 Centre National De La Recherche Scientifique Peptide derivatives, the preparation and their use as elastase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF CLINICAL INVESTIGATION, January 1995, Vol. 95, No. 1, VITIELLO et al., "Development of a Lipopeptide-Based Therapeutic Vaccine to Treat Chronic HBV Infection", pages 341-349. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2771640A1 (fr) * 1997-12-03 1999-06-04 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
WO1999027954A3 (fr) * 1997-12-03 1999-08-26 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire
US7476386B1 (en) 1997-12-03 2009-01-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mixed lipopeptide micelles for inducing an immune response
WO2010086294A2 (fr) 2009-01-28 2010-08-05 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations

Also Published As

Publication number Publication date
AU6103896A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
JP4405594B2 (ja) 改良型固相ペプチド合成及びかかる合成において利用するための試薬
EP0938497B1 (fr) Peptide a structure helicoidale contrainte et leurs procedes de fabrication
US6271198B1 (en) Constrained helical peptides and methods of making same
TWI331155B (en) Insulinotropic peptide synthesis using solid and solution phase combination techniques
EP0534615A2 (fr) Epitopes du virus de l'hépatite B incluisant une réponse CTL rétrécie par HLA
EP0343460A2 (fr) Peptides cs de P. Falciparum comme épitope universel de cellules t
Deprez et al. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL
JP5908478B2 (ja) ｈ「Ｇｌｙ２」ＧＬＰ−２の固相合成
US5019383A (en) Fatty acid carriers for synthetic peptides
KR20070026450A (ko) 자가면역 질환과 관련된 자가 항원 및 비자가 항원의 동정방법
CN101328208A (zh) Hiv肽，抗原，疫苗组合物，检测hiv所诱导的抗体的免疫测定试剂盒及方法
Beekman et al. Synthetic peptide vaccines: palmitoylation of peptide antigens by a thioester bond increases immunogenicity
JP3821305B2 (ja) 細胞障害性ｔリンパ球誘導リポペプチドおよびワクチン
JPH08504090A (ja) 抗−ネコ免疫不全ウイルス（ｆｉｖ）ワクチン
Zeng et al. Synthesis of a new template with a built‐in adjuvant and its use in constructing peptide vaccine candidates through polyoxime chemistry
US7122193B1 (en) Retro peptides, antibodies thereto and their uses for vaccination and in vitro diagnosis
EP0450715B1 (fr) Composés immunogènes, procédé en vue de leur synthèse et leur utilisation dans des vaccins contre la malaria
CA1271717A (fr) Polypeptides utiles dans la vaccination contre les enterovirus
JPH10212300A (ja) ペプチドワクチン
US4857634A (en) Peptides useful in vaccination against enteroviruses
AU732085B2 (en) Vaccine comprising antigens bound to carriers through labile bonds
GB2282813A (en) Annular antigen scaffolds comprising thioether linkages
WO1996040213A1 (fr) Production et purification de peptides
EP0093851A2 (fr) Supports d'acides gras pour vaccins synthétiques
US6379679B1 (en) Multiple branch peptide construction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载